Transgene SA
PAR:TNG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Transgene SA
Operating Income
Transgene SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Transgene SA
PAR:TNG
|
Operating Income
-€35.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Valneva SE
PAR:VLA
|
Operating Income
-€81.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-15%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Income
-€53.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-12%
|
|
|
Inventiva SA
PAR:IVA
|
Operating Income
-€132.6m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Operating Income
-$146.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-12%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Income
-€246.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Transgene SA
Glance View
Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
See Also
What is Transgene SA's Operating Income?
Operating Income
-35.1m
EUR
Based on the financial report for Dec 31, 2025, Transgene SA's Operating Income amounts to -35.1m EUR.
What is Transgene SA's Operating Income growth rate?
Operating Income CAGR 10Y
-2%
Over the last year, the Operating Income growth was 2%. The average annual Operating Income growth rates for Transgene SA have been -5% over the past three years , -8% over the past five years , and -2% over the past ten years .
